Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
Cash Flows From Operating Activities | |||||
Net Income | 3,232,000 | -204,100 | 2,737,600 | 2,408,400 | 2,390,500 |
Depreciation Amortization | 1,609,000 | 1,567,300 | 1,496,600 | 1,427,700 | 1,379,000 |
Income taxes - deferred | 326,800 | -787,900 | 439,500 | -748,400 | 36,800 |
Accounts receivable | -996,700 | -357,000 | -709,400 | -304,500 | 117,400 |
Accounts payable and accrued liabilities | -284,500 | 916,300 | 1,123,800 | 207,900 | -809,000 |
Other Working Capital | -2,378,700 | 3,204,900 | -484,100 | -1,139,200 | -325,500 |
Other Operating Activity | 4,016,600 | 1,276,100 | 247,000 | 1,112,700 | 1,669,200 |
Operating Cash Flow | $5,524,500 | $5,615,600 | $4,851,000 | $2,964,600 | $4,458,400 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 2,440,300 | 1,462,800 | 314,600 | 1,319,600 | 2,416,300 |
PPE Investments | -1,210,600 | -1,076,800 | -963,600 | -973,600 | -1,147,300 |
Net Acquisitions | N/A | -882,100 | -45,000 | -5,283,100 | -551,400 |
Purchase Of Investment | -837,900 | -4,611,600 | -4,346,000 | -3,226,500 | -9,802,700 |
Sale Of Investment | 3,509,500 | 2,586,000 | 2,086,000 | 3,068,400 | 11,009,400 |
Purchase Sale Intangibles | N/A | N/A | N/A | 410,000 | -308,300 |
Other Investing Activity | -1,995,300 | -1,261,900 | -185,100 | 5,122,000 | -5,833,400 |
Investing Cash Flow | $1,906,000 | $-3,783,600 | $-3,139,100 | $26,800 | $-3,909,100 |
Cash Flows From Financing Activities | |||||
Change In Short Term Borrowing | -2,197,900 | 1,397,500 | 1,293,200 | -2,680,600 | 2,680,600 |
Debt Issued | 2,477,700 | 2,232,000 | 1,206,600 | 4,454,700 | 992,900 |
Debt Repayment | -1,009,100 | -630,600 | -200 | -1,955,700 | -1,034,800 |
Common Stock Issued | 1,659,700 | N/A | N/A | N/A | N/A |
Common Stock Repurchased | -4,150,700 | -299,800 | -600,100 | -749,500 | -800,000 |
Dividend Paid | -2,311,800 | -2,192,100 | -2,158,500 | -2,127,300 | -2,101,200 |
Other Financing Activity | -372,800 | -364,400 | -300,800 | -52,600 | 96,100 |
Financing Cash Flow | $-5,904,900 | $142,600 | $-559,800 | $-3,111,000 | $-166,400 |
Exchange Rate Effect | -63,600 | -20,500 | -236,400 | -85,600 | -341,500 |
Beginning Cash Position | 6,536,200 | 4,582,100 | 3,666,400 | 3,871,600 | 3,830,200 |
End Cash Position | 7,998,200 | 6,536,200 | 4,582,100 | 3,666,400 | 3,871,600 |
Net Cash Flow | $1,462,000 | $1,954,100 | $915,700 | $-205,200 | $41,400 |
Free Cash Flow | |||||
Operating Cash Flow | 5,524,500 | 5,615,600 | 4,851,000 | 2,964,600 | 4,458,400 |
Capital Expenditure | -1,210,600 | -1,076,800 | -1,037,000 | -1,066,200 | -1,162,600 |
Free Cash Flow | 4,313,900 | 4,538,800 | 3,814,000 | 1,898,400 | 3,295,800 |